异常DWI升级的PI-RADS 2.1版移行区不典型结节的 前列腺癌患病率:与MRI引导经直肠超声靶向穿刺活检的相关性
回顾性分析2015年1月至2018年7月104例男性109个移行区PI-RADS 2.1版评分≤3结节的靶向活检结果,比较DWI升级的不典型结节(40个)与传统T2WI评分3结节(55个)的前列腺癌检出率。DWI升级结节中任何前列腺癌27.5%、临床显著前列腺癌7.5%,传统评分3结节分别为43.6%和20.0%,差异均未达统计学显著(P=.11和P=.09)。
要点
- DWI升级的移行区不典型结节前列腺癌患病率约28%,临床显著癌约8%。
- DWI升级结节与传统T2WI评分3结节的癌检出率无显著差异(P=.11和P=.09)。
- 未升级的不典型结节中未诊断任何前列腺癌。
核心结论
- DWI升级的移行区不典型结节前列腺癌患病率低(任何前列腺癌约28%,临床显著前列腺癌约8%),临床显著癌检出率与传统T2WI评分3结节相比无显著差异。
研究设计与样本
- 回顾性识别2015年1月至2018年7月间104例男性109个移行区PI-RADS 2.1版评分≤3结节,均行MRI引导经直肠超声靶向活检。
- 三位对评分不知情的放射科医师独立重新评分,采用Cohen kappa评估一致性,并通过第二轮联合复核达成共识诊断。
诊断标准与关键数值
- 临床显著前列腺癌定义为国际泌尿病理学会(ISUP)分级组≥2。
- 共识复核共95个PI-RADS 2.1版3类结节(55个传统T2WI评分3结节和40个DWI升级不典型结节)及14个2类或1类结节。
- DWI升级不典型结节中任何前列腺癌27.5%(11/40)、临床显著癌7.5%(3/40),传统T2WI评分3结节分别为43.6%(24/55)和20.0%(11/55)。
- 任何前列腺癌比较P=.11,临床显著前列腺癌比较P=.09。
- 读者间一致性:读者1与2 κ=0.329,读者1与3 κ=0.548,读者2与3 κ=0.652。
临床应用与阅片要点
- 本研究验证了PI-RADS 2.1版对不典型结节的DWI升级规则,升级结节靶向活检的显著前列腺癌检出率与传统T2WI评分3结节相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. In PI-RADS version 2.1 (v2.1), atypical transition zone (TZ) nodules (homogeneous circumscribed nodules without full encapsulation) assigned category 2 can be upgraded to category 3 when showing markedly restricted diffusion. The prevalence of prostate cancer (PCa) in DWI-upgraded atypical nodules is unknown. OBJECTIVE. The purpose of this study was to evaluate the prevalence of PCa in DWI-upgraded TZ atypical nodules and compare PCa diagnosis rate with that for conventional score 3 TZ nodules. METHODS. We retrospectively identified 104 consecutive cases of men who underwent MRI-directed transrectal ultrasound-guided targeted biopsy of 109 TZ category 3 or lower nodules performed between January 2015 and July 2018. Three radiologists who were blinded to the scores independently rescored lesions using PI-RADS v2.1. Agreement was assessed by Cohen kappa score. Consensus diagnosis was established by a second-round joint review. The number of TZ atypical nodules with or without DWI-upgraded and conventional score 3 TZ nodules were recorded and compared with targeted biopsy results including any PCa or clinically significant PCa (csPCa, defined as International Society of Urological Pathology [ISUP] grade group ≥ 2) using chi-square analysis. RESULTS. There were 95 PI-RADS v2.1 category 3 (55 conventional T2-weighted MRI score 3 and 40 DWI-upgraded atypical nodules) and 14 category 2 or 1 nodules at consensus review with patient mean age of 64.8 ± 8.4 (SD) years, PSA of 10.6 ± 7.2 ng/mL, and nodule size of 15.1 ± 5.5 mm. Interobserver agreement ranged from slight to substantial for radiologists 1 and 2 (κ = 0.329), radiologists 1 and 3 (κ = 0.548), and radiologists 2 and 3 (κ = 0.652). From the 40 upgraded atypical nodules, 27.5% (11/40) had PCa and 7.5% (3/40) had csPCa (8 ISUP grade 1, 2 ISUP grade 2, 1 ISUP grade 3), compared with 43.6% (24/55) PCa and 20.0% (11/55) csPCa (13 ISUP grade 1, 6 ISUP grade 2, 3 ISUP grade 3, 2 ISUP grade 4) diagnosed in conventional T2-weighted score 3 nodules (p = .09 for csPCA and p = .11 for PCa). PCa was not diagnosed in any atypical nodule that was not upgraded on DWI. CONCLUSION. The prevalence of PCa in DWI-upgraded TZ atypical nodules was low (≈ 28% for any PCa and ≈ 8% for csPCa) and compared favorably to csPCa diagnosis rates in conventional TZ score 3 nodules. CLINICAL IMPACT. This study validates the DWI upgrade rule introduced in PI-RADS v2.1 for atypical nodules, which showed significant prostate cancer detection rates at targeted biopsy similar to those of conventional T2-weighted MRI TZ score 3 nodules.
引用
- Lim CS, Abreu-Gomez J, Carrion I, et al. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy. AJR Am J Roentgenol. 2021. PMID: 32755208. doi:10.2214/AJR.20.23932
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。